Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

Based on the 10Q no conversions in the last year.

All the stock sold was gifted to note holders via "make good provision(s)" in the notes. The get millions of free shares and simply wait to then free them up and sell them.

No point in staying OTC only to have to reverse the stock for no reason. This also means that their acquisition "business" is a NO GO, they are not going to raise $30 million to acquire a construction business while on the Pink Sheets.

They basically gave away the ending. BTW... Their website looks to be down, so they probably can't even afford to pay the hosting fees, lol.

[Craig305]

That is strange. Wonder if that might be a mistake when the delinquent reporting status was removed?
Or maybe Collier is throwing in the towel and going pink to reduce filing fees (cheaper as Pink status).

[Biotech_Tradez]

Looks like ENDV is now on the PINK SHEETS!

This dog has fleas. and has been nothing but a loser since it was incorporated.

Collier has done nothing to generate a single cent of value, yet his equity has only increased. Someone explain that to me?

[John_Vallay]

I would love to have some of these promoters come on this message board to explain to us how great endonovo is now.

I would really love Alan Collier to issue a press release about Q3 results and HE/HIM make comments on how great things are at the company.

This is the guy that years ago gave guidance of $300 million in sales.

How, why and who buys a single share of this stock is a mystery to me

ZERO CASH + NO SALES, but yet they come out with construction deals and $50 million valuations and uplistings to Nasdaq. AND SOME HOW PEOPLE STILL BUY SHARES. Sucker born every minute.

[Biotech_Tradez]

They ended the year Sub-Penny and with no cash.

They have no money to pay for their upcoming audit. They are going to need to really dilute the stock to even raise enough money to get the audit done, let alone do anything else.

I knew that the 8k they put out a couple of weeks ago was a pump to sell stock and the $15k they received for signing that agreement was just to be able to pay for the more than 45 day late quarterly filing.

This company is insolvent and will continue to lose money for everyone involved with the exception of Collier, who has set himself up to steal from the shareholders.

[Craig305]

The sales continue to be from the same buyer.

"During the nine months ended September 30, 2023, we had one significant customer, which accounted for approximately 100% of sales."

[Biotech_Tradez]

NO CASH, $1,500 IN SALES & $24M IN LIABILITIES!

[Biotech_Tradez]

10Q Out and It's a disaster! Run!!

[brojazzy]

Scam alert

[Biotech_Tradez]

Fire sale at ENDV! People selling losers.

[Biotech_Tradez]

Based on the clinical trial that was conducted at Columbia SofPulse doesn't work.

Just scroll down to the pain scores results. A local numbing agent is more effective at 1 hour post mastectomy and just as effective at 3 weeks. When you combine the company's contraption with the numbing agent then it actually becomes less effective.

This study basically shows that the company's contraption is not really needed and current local numbing agents work fine and better than if combining the two. But hey since these studies don't allow the company to market their stock it won't be highlighted by the company.

PEMF and PEC Blocks in Mastectomy Reconstruction Patients

[John_Vallay]

has sofpulse any sales

has sofpulse been proven to work

https://www.msn.com/en-us/money/companies/sec-charges-ex-ceo-of-medical-device-company-with-fraud-says-some-devices-were-just-a-piece-of-plastic/ar-AA1lL2re?ocid=msedgntp&pc=HCTS&cvid=cf2dbbfe20b7444089c1f4e2e6c26e86&ei=30

[Biotech_Tradez]

Collier got $15k to pay for the 10Q from Ira based on the 8K.

ENDV received $15,000 in cash as part of signing the definitive purchase agreement.Now he can pay the accountants to file the month late quarterly filing. Makes sense, they have no cash and no way to raise money.

[brojazzy]

SCAM

[Craig305]

Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million

Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party's asset valuation acceptable to the Endonovo board. It was further agreed, that SofPulse, Inc. will prepare to fulfill the regulatory requirements for a NASDAQ listing following the sale's completion.

To fuel SofPulse, Inc. operations, the company aims to conduct a capital raise of up to $500,000 through a 506 offering tailored for accredited investors. At a pre-money valuation of $10 million and shares priced at $2.50 per share, the capital raise is anticipated to support further development and growth.

"The acquisition of the SofPulse® assets is a major step in the ongoing transformation of the SofPulse® brand, as we execute our strategic priorities, intensifying our focus and augments the value for all our shareholders.": commented, Ira Weisberg, President of SofPulse, Inc.

Valuation

In 2018, the ENDV-valued assets to be purchased by SofPulse, Inc. were valued at $75 million by a third-party valuation firm. As a condition of the announced sale of the SofPulse® assets, it was agreed that they would update the previous valuation with a qualified third party acceptable to both the Endonovo’s board and SofPulse, Inc., to establish the purchase price.

Upon signing of the definitive agreement, the sole ENDV board member shall receive super majority voting rights in preferred shares until the entire acquisition price is fulfilled.

Stock Issuance to Endonovo Shareholders

As consideration for the purchase from Endonovo, SofPulse Inc. shall issue $50 million in restricted stock, priced at $5.00 per share. Approximately 80% of the issuance shall be issued ENDV’s shareholders for this transaction, either as a stock dividend or through an alternative mechanism.

In addition to the stock issuance, SofPulse, Inc. has agreed to pay ENDV any additional sum assessed by a third-party valuation report (estimated to be between $50,000,000 to $100,000,000). This payment will initially be paid through a senior note which can be paid in cash or marketable securities listed on NASDAQ after the third-party evaluation concludes.

ENDV will continue the operations of its mergers and acquisitions division, its telehealth division (which SofPulse has agreed to be a customer with a five-year contract), and the further development of its non-medical device business.

Purchase Price Settlement and Capital Raise

The remaining purchase price owed to ENDV will be resolved through a secured promissory which will be convertible into NASDAQ listed marketable securities at the sole discretion of the Seller.

The transaction is anticipated to conclude on December 31, 2023, pending the customary regulatory approvals and satisfaction of other closing conditions. These include the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act.

Future Outlook and Expansion Plans

Upon acquisition, SofPulse, Inc. is set to explore an assortment of growth opportunities. The company's strategic vision encompasses numerous initiatives aimed at swift and substantial revenue expansion.

"By expanding SofPulse® VA and Department of Defense contracts through the Federal Supply Schedule, developing a comprehensive telehealth platform through Endonovo’s technology, growing both domestic and international surgical and pain management markets, alongside robust research and development strategies, SofPulse Inc. is strategically positioned to leverage the commercialization of SofPulse® brand assets and IP. Focusing on sales and marketing efforts to expand these programs and venturing into new consumer markets, SofPulse® is geared towards reaching annualized revenues of approximately $100 million by 2025. ": Weisberg concluded.

[Cornerstone_Marketing]

$ENDV Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million

“As consideration for the purchase from Endonovo, SofPulse Inc. shall issue $50 million in restricted stock, priced at $5.00 per share. Approximately…

— Endonovo Therapeutics, Inc. (@EndonovoInc) December 5, 2023

[Biotech_Tradez]

It is now worth AT LEAST $50M, lol.

The valuation is basically whatever the note holders will accept and it will probably also include warrants or some kind of make whole provision to ensure they at least get their principal back before shareholders see a dime. That means shareholders will be screwed over.

In over 5 years since they acquired these assets, they have not generated any revenue. They abandoned all their clinical trials for traumatic brain injury and all other trials they were pursuing.

[Craig305]

ENDV purchased the Sofpulse assets from Rio Grande for $4.5M and now it is worth $50M ?
Alrighty then! This does not quite pass the smell test.

[Biotech_Tradez]

This deal stinks of SELF DEALING!

The transaction is essentially an arms-length transaction designed to benefit Collier and his cronies as well as pay off the debt holders.

Notice they still don't have a valuation from their third-party, Ocean Tomo, that was to be completed in the first quarter. I suspect that the valuation was nowhere near $50 million so they now are shopping around for someone to basically rubber stamp their own made up valuation.

They have no revenue besides the revenue they generated when their former President bought $300k in devices using a company he formed. It is not directly mentioned but it is alluded to in the filings. This is borderline fraud because it is not a real customer but rather an insider looking to manipulate shareholders into thinking the company has a legit business.

Collier and his cronies have personally enriched themselves via stock options and stock grants and stand to reap all the benefits of this proposed transaction meanwhile they have driven the company into the ground. The stock has lost 99.9% of its value in the last 5 years.

This press release has one simply goal - PUMP THE STOCK so that they can sell shares to pay for their quarterly filings and annual filing coming up. Looking at the trading volume today it has accomplished its goal.

[John_Vallay]

To keep this really simple, and if anyone sees a mistake in my overview and simplicity please let me know.

Endonovo is selling the Sofpulse assets to SofPulse Inc. for no less than $50 million.

SofPulse Inc is a company started by Endonovo.

Endonovo has no money, in fact they have over $20 million in debt. That probably means SofPulse Inc has no money, so in simple terms Endonovo is selling something that has no sales to their own company a product for $50 million.

I feel sad and sorrow for anyone that buys ENDV shares on the open market because they think Endonovo is getting $50 million.
I can not envision any bank taking SofPulse Inc public on Nasdaq via IPO.

I am disappointed on the level to which some people try to deceive other people, but after following Endonovo for a few years I am not surprised.

If you notice, Alan Collier names does not appear in today's press release. In fact his name has not appeared in many of the latest press releases. I guess it's his attempt of shielding himself from lawsuits, warrants, inquiries and arrest.

Oh and by the way, they are doing all these things, and they can not file a 10Q.

Sometimes I laugh so hard it's a shame on how some people really deceive unsophisticated investors into buying stock, or in this case, SofPulse Inc is raising $500,000 through a private placement.

SofPulse Inc is raising $500,000, but they announced they are buying sofpulse assets for no less than $50 million.

[Craig305]

8K announcement.

On December 3, 2023, the Company entered into a definitive Asset Purchase Agreement with SofPulse, Inc., a Delaware corporation ("SPI"), to acquire the SofPulse® Assets which represents the technology, both patented and proprietary, inventories and contract rights relating to the Company's SofPulse® Electroceutical® device as it relates to medical use. The Company has retained rights to the non-medical applications of SofPulse® and will continue the development of its tele-health business. The purchase price under the Asset Purchase Agreement shall be no less then $50 Million and shall be fixed to equal the amount of a third party evaluation of the SofPulse® Assets which will be completed before the closing under the Asset Purchase Agreement. $50 Million of the purchase price for the SofPulse® Assets will be paid by the issuance of SPI stock to the Company tentatively valued at $5 a share but to be adjusted to be equal to the per share price in SPI's IPO (which may or may not ever occur) and the balance to be in the form of cash or note. The Closing under the Asset Purchase Agreement is subject to shareholder approval by the Company and other conditions.The foregoing is only a summary of the Asset Purchase Agreement and the reader is referred to the agreement, which is an exhibit to this report for its full terms and conditions.

[retired early]

The REVENGE of the MOUSE. :0

[Biotech_Tradez]

ENDV is INSOLVENT.

They don't have the money to pay their accountants to finish the 10Q.

They cannot get more money from their toxic lenders because they can no longer convert their debt into freely traded stock at large discounts.

Those lenders are no longer lending to ENDV because they cannot get out their money and ENDV cannot get new investors because:

1.) They are north of $10 million in debt so their subordinate investments would be lost in an ever increasingly likely bankruptcy
2.) Any new investment is going to go directly to repaying debt and interest and not into the actual business, which leads me to:
3.) ENDV has no actual business, all it does is issue press releases and sell stock, and no means to create a viable business because its CEO is unqualified.

[Craig305]

It is strange how late they are. They have never been this late before.
The NT delay document says the delay is NOT due to a significant change.

[Biotech_Tradez]

$3 (300 shares) bought in last minute to manipulate stock.

ENDV management is pathetic. They clearly have to sell a ton of stock to be able to pay for their 10Q which is two weeks late.

[brojazzy]

Bloodbath for this scam

[Biotech_Tradez]

I believe they have to stay listed in order to not be in complete default and end up sued.

The cost to finish the quarterly filing is less than the legal fees from lawsuits and a bankruptcy. The results are unaudited anyway.

I remember back during COVID ENDV was being sued by Auctus fund and Collier had signed a confession of judgement and I believe he had a personal guarantee on that debt. That debt was likely bought by another creditor so he is still on the hook for that.

[John_Vallay]

They don't have any cash
They have over $20 million in debt

Collier has taken as much as possible from shareholders through the issuance of convertible notes to funds at a discount to market

They don't need to legally file anymore as they are winding down operations and going away.

Collier will face lawsuits from the funds that he issued convertible notes to, but once a bankruptcy is filed the whole thing will go away. ENDV will be 0001 a share very soon and most shareholders will just be bitter and move on with their lives because it doesn't pay for most shareholders to pursue Endonovo legally and they will not get any cash even if they win a court case because the company does not have any cash to pay off.

Endonovo is a C Corp which means Alan Collier personally has absolutely zero liability for Endonovo's debt.

The only way Alan Collier will face any consequences is if one of those convertible note holders decides to pursue Collier personally for misleading and fraudulent business practices & press releases. I am going to imagine that the convertible note holders will hire a lawyer to determine if Collier has any personal worth that would be worthwhile to pursue in court.

If Collier personally has little to nothing than most funds that do these convertible notes will not pursue anything because it will cost them money for lawyer.

This is a classic case of an investment into a bad company with a low-life CEO, and just accept the losses and move on. Kick yourself in the butt for not doing proper due diligence.

[Craig305]

ENDV is 2 days past the deadline to file their financials after the NT extension.
OTC Markets now has ENDV tagged as "Delinquent SEC Reporting".

[Craig305]

Looks like ENDV is waiting to file NT (delay notification) for the last minute.

[retired early]

Now's you chance, man the life rafts. :) Revenge of the NUDE mouse.

[brojazzy]

Collier should spend Christmas locked up in the penitentiary

[Biotech_Tradez]

I bet Collier gets a huge Christmas Bonus for screwing over the shareholders!

[Biotech_Tradez]

How long until Collier puts out a FAKE NEWS PR to pump it up?

I guess that acquisition isn't going through otherwise we would have heard something since they did announce a binding LOI over 1 year ago. I guess that the PEMF assets are not worth over $75 million since that valuation report that was promised in march has suddenly disappeared. I guess all that revenue they promised was suddenly misplaced.

[Biotech_Tradez]

Back to SUB-PENNY. What a POS!

[John_Vallay]

Cornerstone Marketing is back. Thank you for your paid promotional insight. You have a number of alias on this board and you have been positive on ENDV in all your posts. Since you are back I am thinking Alan must have paid you to restart posting positive things about the company.

I am not going to ask you a question or make a statement about ENDV because you will refute it because you are paid to do so.

I will simply state that ENDV past sales is in fact indicative of future sales and their debt is what it is.

[retired early]

Oh that poor NUDE mouse. :(

[Biotech_Tradez]

Yay!!! More places to NOT generate sales! LOL!!!

[Cornerstone_Marketing]

Next up EU approval in 2024

Also working on Direct to consumer and telehealth.

Seems like a ticking time bomb

[Biotech_Tradez]

LOL. Nice try sport. No Studies means no sales. Other devices sell because they have very large clinical trials not a bunch of small feasibility studies. BTW, the clinical trial at Columbia University they kept touting failed, look it up.

[Monroe1]

Not worried in the least and neither are most investors here and elsewhere. Which is why the pps is starting to move. Devices and new drugs sometimes take awhile to take off especially when in the medical world change only comes from the fda which has many tricks up their sleeve both inside and out of Pharma at large. Has covid not made this loud and clear? You are wrong on your assessment of Taiwan and the far east too. They are more open and advanced. Have you noticed a lot of Chinese Traditional Medicine has been around for thousands of years? And still only accepted by those in the west who study or have used such
products. So keep an open mind about the acceptance in the far east where acupuncture has lived on forever only slowiy having gained acceptance in the USA thanks to the fda controlled mindset of closed thinkers.

Expecting this to take time of course as it has already shown, but now it is time for progress being made presently. All things in their own time. Timing is everything in stock trading.

$Endovo$

[Biotech_Tradez]

Pay attention bud. They are raising $5m with a $4m market cap = dilution.

They also have $20 million in debt including more than $10 million in convertible debt and interest that is past due. This offering specifically states that they can exchange freely traded shares for debts owed by the company, which means it is just a slimy way to circumvent the halt on the conversion of debt to freely traded stock.

This device has been on the market in the US since 2008 which is 15 years and yet it still doesn't sell. What makes you think Taiwan will be any different? It won't. I get it you looked at the chart and think its a good flip so you want to push anything as being good news, but its not. Maybe you flip it and make some money like PennyStockSnipers did, but he is a penny stock pump and dumper. Long term investors should run for the hills.

[Monroe1]

Interesting. Crossed above 200 day average today.
Would more foreign approvals follow? Could this
mean revenue? Seems that way. Go Taiwan.

[Biotech_Tradez]

Bragging about increasing the market cap by 280% via dilution.

Talk about putting lipstick on a pig!

Notice how they simply keep moving the goal post to keep raising money to fund their lifestyles.

[Craig305]

ENDV investor/investment website
https://endv-investment-site.webflow.io/

[John_Vallay]

I do not know how any ENDV investor thinks Taiwan FDA approval is good for Endonovo.
Endonovo can be selling SofPulse device here in the United States, but it has no sales. It has no sales in a Country (United States) that they supposedly know how to do business in.

Why in the world would the Taiwan medical community use the device?
I will go one step further, the device wasn't sold by IVIVI, the device wasn't sold by ADM and the device hasn't sold with all the years Endonovo has had it.

Maybe the device simply sucks. Endonovo over the years has had multiple distributors and distribution agreements, but yet no sales. I am sure those distributors have legitimate sales channels, BUT NO SALES. Endonovo claims to be in VA hospitals, but yet np sales. Endonova gave the HFL the device, but yet no sales.

Maybe the device has no real value given that many companies have tried to make a go-of-it. Not to mention that Endonovo has tried everything to make a go of it, yet no sales.

Maybe they have a product that either sucks, or has no legitimate value.

Taking all of that into consideration, Alan Collier probably knows there is no value to the device, but he has used the capital markets to raise money and pay himself a salary as well as I am sure reimbursements for many things from travel, to meals to cars, insurance, and so on and so on.

The real question now is can he raise any more money through those convertible notes, or will he have to go out and get a job. ENDV liquidity has gone down that it would be difficult to impossible to raise money through convertible notes. Not to mention that Endonovo $23 million in debt which included $7 million in outstanding convertible notes and $4 million in interest that is due from past convertible notes. I am guessing that those convertible note holders want to get paid so no one is going to give him any more notes and he is so delinquent on his accounts payable that he must be facing many lawsuits.
I can not see any scenario that he would be able to raise a single penny.

Unless he has saved money, he will need to go out and get a job. What will he write on the job application that he has done for the past 10 years and where would he be applying to?

I can not imagine any medical business will hire him.
I can not imagine any financial firm would hire him.

Does he go to a retailer like Home Depot to take any job they have open.

I think there should be a website dedicated to the trials and tribulations of Alan Collier.
TRIALS - Criminals trials would be interested - the guy once issued a press release that Endonovo was going to do over $300 million in revenue. That was so misleading that it justifies criminal pursuit.
TRIBULATIONS - Most misleading dishonest CEO's get caught and when the go before a sentencing judge they cry and beg for mercy and claim they were wrongfully advised and blah, blah, blah. They claim to suffering and they didn't know better at the time and blah, blah blah.

What will be Collier's trials and tribulations given his misleading press releases, years of utter and complete failure, but successful in raising $40 million as a result of those misleading press releases.

YEAH- SALES IN TAIWAN ARE GOING GOING TO BE WONDERFUL !!!!

[Biotech_Tradez]

This does not matter, only revenue matters. They have none.

Funny how they put it into an 8k when this isn't a material event, yet all the other negative things that are material events are not put into 8k's but rather are buried into the notes in the quarterly and annual filings. Clearly they are just looking to pump the stock so they can continue to sell toxic debt into the market to fund their lifestyles and pay for the filings.

When the 10Q for the third quarter comes out, you will see that they are not selling squat, the only revenue will be the amortized portion of the one purchase they got from a related party, which I am 99.9% certain was from their former President Michael Mann.

[Craig305]

8K released regarding Taiwan.

On October 10, 2023, the Company was advised by Evermed, its distributor in Taiwan, that the Taiwan Food and Drug Administration had granted a license to the Company’s SofPulse® device for medical use in Taiwan.

[Biotech_Tradez]

Its been over 1 year since they announced a "definitive agreement" to buy that concrete company.

From the press release dated 9/27/22

Closing of the transaction is estimated to be by December 15, 2022. The proposed acquisition has been approved by the both the Board of Directors of Endonovo and Western Star’s owner.

It is clear now that this transaction is not happening and will be simply swept under the rug probably buried amongst other bad news in the 10K. There is simply no way that the idiots running ENDV can raise the money to acquire this company and I doubt the owners of the concrete company would be stupid enough to take a bunch of worthless stock that could double as toilet paper.

Also, the "valuation report" for the PEMF assets is now over 6 months late.

From the press release dated 1/31/23

Ocean Tomo’s analysis is expected to be completed in the first quarter of 2023. Once the proposed spin-off is fully structured and the necessary agreements are completed, Endonovo will prepare the appropriate filings with the SEC and provide information to shareholders.

It is clear that Ocean Tomo refuses to give Collier the phony valuation in excess of $75 million that he claims he got back in 2018. Or maybe Collier cannot pay them so they will not release it. Probably both to be honest. Collier looks to be just another scam artist moving from scam and scheme to scam and scheme and in the process screwing over every investor he takes money from. I hope the company is thrown into BK soon and gets bought by someone actually interested in bringing the technology to market.

[Biotech_Tradez]

Well they probably are not getting paid by collier and they are not performing well either.

No liquidity in the stock besides the conversions being dumped on the bids.